Latest Conference Articles

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

Jim Mazzo is among the presenters who will highlight the need to break silos and accelerate eye health solutions at the Collaborative Community on Ophthalmic Innovation (CCOI) meeting at Stanford University on July 23, 2025.

Ophthalmologists discuss the most impactful advancements reshaping patient care over five decades.

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations that defined modern ophthalmology.

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in vision and safety.

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision and combat global blindness.

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing reliance on low vision centers.

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Advanced monitoring strategies are overcoming significant obstacles in retinal care, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Fluorescence lifetime imaging ophthalmoscopy is emerging as a valuable tool to reveal previously hidden links between retinal changes and systemic disease.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery

Siegfried Priglinger, MD discussed research he presented focused on pediatric patients with inherited retinal diseases with an emphasis on studies into the RPE65 gene.

Mark Daly discusses the transformative role of AI in ophthalmology, highlighting its potential to enhance patient care and streamline physician workflows.

Jay Chhablani, MD, explains how 3D choroidal vessel segmentation transforms ophthalmology, enhancing disease diagnosis and treatment through advanced imaging technology.

The ELEVATUM study explored faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities, showcasing significant visual acuity improvements.

Researchers share that perfluorohexyloctane eye drops offer rapid relief for dry eye disease, enhancing patient comfort before cataract surgery.

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, offering reduced risks and improved outcomes.

At the 2025 ASCRS meeting, Dr. Sarkisian presented 3-year data on the iDose TR from the FDA clinical trial.